Blood-based HYAL2 methylation as a potential marker for the preclinical detection of coronary heart disease and stroke.

Background: Coronary heart disease (CHD) and stroke have become the leading cause of premature mortality and morbidity worldwide. Therefore, sensitive and accurate biomarkers for early detection of CHD and stroke are urgently needed for effective prevention and treatment. We aim to investigate the association between blood-based HYAL2 methylation and the risk of CHD and stroke in Chinese population.

Association between the methylations of in peripheral blood and lung cancer: a case-control study.

Background: is hypermethylated in multiple cancers. also functions as a regulator of tumors. However, there are only very few reports on the association of methylation of and with lung cancer (LC) in peripheral blood.

gene methylation in peripheral blood as a potential biomarker for breast cancer detection.

Background: Aberrant DNA methylation has been identified as biomarkers for breast cancer detection. Coiled-coil domain containing 12 gene () implicated in tumorigenesis. This study aims to investigate the potential of blood-based methylation for breast cancer detection.

hypomethylation as a biomarker for distinguishing benign and malignant breast tumours.

Some benign and malignant breast tumours are similar in pathological morphology, which are difficult to be distinguished in clinical diagnosis. In this study, we intended to explore novel biomarkers for differential diagnosis of benign and malignant breast tumours. Methylation EPIC 850K beadchip and RNA-sequencing were used to analyse 29 tissue samples from patients with early-stage breast cancer (BC) and benign breast tumours for differently methylated and expressed genes.

Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.

Background: Non-small cell lung cancer (NSCLC) accounts for the vast majority of lung cancers. Early detection is crucial to reduce lung cancer-related mortality. Aberrant DNA methylation occurs early during carcinogenesis and can be detected in blood.

methylation as a cancer biomarker in differentiating papillary thyroid cancer from benign thyroid nodules.

It remains a challenge to accurately identify malignancy of thyroid nodules when biopsy is indeterminate. The authors aimed to investigate the abnormal DNA methylation signatures in papillary thyroid cancer (PTC) compared with benign thyroid nodules (BTNs). The authors performed genome profiling by 850K array and RNA sequencing in early-stage PTC and BTN tissue samples.

DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules.

Differentiation between benign and malignant thyroid nodules has been a challenge in clinical practice. Exploring a novel biomarker to determine the malignancy of thyroid nodules has important implications. We semi-quantitatively determined the DNA methylation levels of four CpG sites located at the gene body of HYAL1 in formalin-fixed paraffin-embedded (FFPE) tissue samples from 190 early-stage papillary thyroid cancer (PTC) cases and 190 age- and gender-matched subjects with benign thyroid nodule (BTN).

Identification of an association between coronary heart disease and ITGB2 methylation in peripheral blood by a case-control study.

Background: Blood DNA methylation was associated with coronary heart disease (CHD) risk in Caucasians. We investigated the association between DNA methylation in peripheral blood at the reported loci and CHD in the Chinese population.

Methods: The integrin subunit beta 2 (ITGB2) gene was identified in 196 CHD cases and 184 controls, and its methylation level was determined by mass spectrometry.

Hypomethylation of DYRK4 in peripheral blood is associated with increased lung cancer risk.

Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. It is urgent to identify new biomarkers for the early detection of LC. DNA methylation in peripheral blood has been reported to be associated with cancers.

Hypomethylation of ABCG1 in peripheral blood as a potential marker for the detection of coronary heart disease.

Background: Novel molecular biomarkers for the risk assessment and early detection of coronary heart disease (CHD) are urgently needed for disease prevention. Altered methylation of ATP-binding cassette subfamily G member 1 (ABCG1) has been implicated in CHD but was mostly studied in Caucasians. Exploring the potential relationship between ABCG1 methylation in blood and CHD among the Chinese population would yield valuable insights.

The association between methylation in peripheral blood and breast cancer in Chinese women.

Purpose: Previous studies have shown that DNA methylation in peripheral blood may be associated with breast cancer (BC). To explore the association between the methylation level of the Cathepsin Z gene in peripheral blood and BC, we conducted a case-control study in the Chinese population.

Methods: Peripheral blood samples were collected from 567 BC cases, 635 healthy controls, and 303 benign breast disease (BBD) cases.

Identification of FUT7 hypomethylation as the blood biomarker in the prediction of early-stage lung cancer.

Early detection of lung cancer (LC) is vital for reducing LC-related mortality. However, noninvasive diagnostic tools remain a great challenge. We aim to identify blood-based biomarkers for the early detection of LC.

HTRA1 methylation in peripheral blood as a potential marker for the preclinical detection of stroke: a case-control study and a prospective nested case-control study.

Background: Stroke is the leading cause of mortality in China. DNA methylation has essential roles in multiple diseases, but its association with stroke was barely studied. We hereby explored the association between blood-based HTRA serine protease 1 (HTRA1) methylation and the risk of stroke.

Hypomethylation of RPTOR in peripheral blood is associated with very early-stage lung cancer.

Purpose: Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Novel biomarkers for LC detection are urgently needed. Here we aimed to investigate the association between RPTOR methylation in peripheral blood and LC.

The association between methylation in peripheral blood and coronary heart disease in a case-control study.

Background: Coronary heart disease (CHD) brings a heavy burden to society worldwide. Novel and minimally invasive biomarkers for the risk evaluation of CHD are urgently needed. Previous study has revealed that blood-based hypomethylation of β-actin () was associated with increased risk of stroke, but not reported in CHD yet.

The association between DNA methylation of 6p21.33 and AHRR in blood and coronary heart disease in Chinese population.

Background: Early detection could significantly improve the prognosis of coronary heart disease (CHD). In-invitro diagnostic technique may provide a solution when sufficient biomarkers could be identified. Pertinent associations between blood-based aberrant DNA methylation and smoking, the pathogenesis of atherosclerosis, and CHD have been robustly demonstrated and replicated, but that studies in Chinese populations are rare.

The Association Between Breast Cancer and Blood-Based Methylation of , and in the Chinese Population.

Recent studies have identified DNA methylation signatures in the white blood cells as potential biomarkers for breast cancer (BC) in the European population. Here, we investigated the association between BC and blood-based methylation of cluster of differentiation 160 (), inositol-3-phosphate synthase 1 () and RAD51 paralog B () genes in the Chinese population. Peripheral blood samples were collected from two independent case-control studies with a total of 272 sporadic early-stage BC cases (76.

The influence of blood sample processing on blood-based DNA methylation signatures.

Stability is crucial for the clinical applicable biomarker such as DNA methylation profiles. However, the influence of various blood processing on the DNA methylation signatures have been barely studied. Here, we systematically evaluated the impact of temporary storage and frozen and thaw on the levels of DNA methylation.

Methylation in the Peripheral Blood as a Potential Marker for the Detection of Coronary Heart Disease: A Case-Control Study.

Previous work has shown the association between blood-based methylation of coagulation factor II receptor-like 3 gene () and cardiovascular mortality in Caucasians. However, the diagnostic value of methylation for CHD is still unknown. The aim of our study was to evaluate the association between blood-based methylation and the risk of CHD in the Chinese population.

methylation in peripheral blood as a potential marker for the early-stage lung cancer: a case-control study in Chinese population.

Background: Lung cancer (LC) is the leading cause of cancer-related morbidity and mortality in China. Exploring novel biomarkers for the early detection of LC is important.

Materials And Methods: We quantified DNA methylation levels of three CpG sites of gene in peripheral blood in 163 early-stage LC cases (88.

Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma.

Background: Early detection is essential to improve the survival of lung cancer (LC). The quantitative measurement of specific DNA methylation changes in the peripheral blood could provide an efficient strategy for the detection of early cancer.

Objective: We applied a candidate approach and assess the association between blood-based SH3BP5 methylation and the risk of lung adenocarcinoma (LUAD) in a case-control cohort.

RPTOR methylation in the peripheral blood and breast cancer in the Chinese population.

Background: Altered regulatory-associated protein of mTOR, complex 1 (RPTOR) methylation levels in peripheral blood was originally discovered as breast cancer (BC)-associated risk factor in Caucasians.

Objective: To explore the relationship between RPTOR methylation and BC in the Chinese population, we conducted two independent case-control studies.

Methods: Peripheral blood samples were collected from a total of 333 sporadic BC cases and 378 healthy female controls for the DNA extraction and bisulfite-specific PCR amplification.

The Association Between Methylation in Peripheral Blood and Early-Stage Lung Cancer in a Case-Control Study.

Purpose: Lung cancer (LC) brings great burden to the society worldwide. Exploring novel biomarkers in vitro for the early detection of LC would be of great importance.

Patients And Methods: We measured DNA methylation levels of 21 CpG sites within Patatin-like phospholipase domain containing 2 () gene in the peripheral blood of 168 early-stage LC cases (94.

Methylation in Blood as a Potential Marker for the Pre-clinical Detection of Stroke: A Prospective Nested Case-Control Study.

Background: Stroke is the second leading cause of death worldwide. If risk of stroke could be evaluated early or even at a preclinical stage, the mortality rate could be reduced dramatically. However, the identified genetic factors only account for 5-10% of the risk of stroke.